Variabilité génétique du virus de l'hépatite C : Implications cliniques

Gastroenterologie Clinique et Biologique

Volumn 24, Issue 2, 2000, Pages 175-184

  Asselah, Tarik ^a   Martinot, Michèle ^a   Boyer, Nathalie ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Diagnosis; Genetic variability; Genotypes; Hepatitis C virus; Quasispecies; Treatment

Indexed keywords

CLASSIFICATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; REVIEW; VIROLOGY;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; VARIATION (GENETICS);

EID: 0001621937     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolution of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.
3. Lunel F. Virus de l'hépatite C : le virus responsable de la plupart des hépatites non A non B. Gastroenterol Clin Biol 1992;16:518-36.
4. Bréchot C. Hepatitis B and C viruses and primary liver cancer. Baillere's Clin Gastroenterol 1996;10:335-73.
5. Saiki RK, Gelfand DH, Stoffel S, Scharfs J, Higuchi R, Horn GT, et al. Primer directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 1988;239:487-90.
6. Ali N, Jameel S. Direct detection of hepatitis C virus RNA in serum by reverse transcription PCR. Biotechniques 1993;15:40-2.
7. Enomoto N, Takada A, Nakao T, Date T. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 1990;170:11021-5.
8. Ulrich PP, Romeo JM, Lane PK, Kelly I, Daniel LJ, Vyas GH. Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest 1990;86:1609-14.
9. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Comm 1991;175:220-8.
10. Houghton M, Weiner A, Han J, Kuo G, Choo QL. Molecular biology of hepatitis C viruse : implications for diagnosis, development and control of viral disease. Hepatology 1991;14:381-8.
11. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl acad Sci USA 1991;88:3382-96.
12. Okamoto H, Kojima M, Okada S, Yoshizawa H, Izuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during 8.2 year infection in a chimpanzee : variability and stability. Virology 1992;190:894-9.
13. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes : quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-9.
14. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, et al. Sequence variability in the 5'non-coding region of hepatitis C virus : identification of a new a new virus type and restrictions on sequence diversity. J Gen Virol 1993;74:661-8.
15. Simmonds P, Alherti A, Alter HJ, Bonino F, Bradley DW, Bréchot C, et al. A proposed system for the nomenclature of hepatitis c virus genotypes. Hepatology 1994;19:1321-4.
16. Mizokami M, Gojobori T, Lau JYN. Molecular evolutionary virology : its application to hepatitis C virus. Gastroenterology 1994;107:1181-2.
17. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21: 570-83.
18. Bukh J. Genetic heterogeneity of hepatitis c virus : quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
19. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol 1997;78:2397-410.
20. rd edition. Philadelphia : Lippincott-Raven, 1996:931-59.
21. Francki RIB, Fauquet CM, Knudson DL, Brown F. Classification and nomenclature of viruses : fifth report of the international commitee on taxonomy of viruses. Arch Virol 1991;2 (suppl):223.
22. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25:1527-38.
23. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus enveloppe and NS1 proteins and the pestivirus enveloppe glycoproteins. Virology 1991;180: 842-8.
24. Stuyver L, Van Arnhem W, Wyseur A, Hernandez F, Delaporte E, Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B reegions and identification of five additional subtypes. Proc Natl Acad Sci USA 1994;91:10134-8.
25. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997;78:321-8.
26. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P, and the international HCV collaborative study group. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions ; implications for virus classification. J Gen Virol 1995;76:2493-507.
27. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing of hepatitis C virus by polymerase chain reaction with type-specific primers : application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
28. Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol 1991;72:2105-12.
29. Davidson F, Simmonds P, Ferguson J, Jarvis L, Dow B, Follett E, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5'non-coding region. J Gen Virol 1995;76:1197-204.
30. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
31. Ravaggi A, Zonaro A, Grazia Marin M, Puoti M, Albertini A, Cariani E. Distribution of viral genotypes in Italy determined by hepatitis C virus typing by typing by DNA immunoassay. J Clin Microbiol 1994; 32:2280-4.
32. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, et al. Typing of hepatitis C virus iolates by DNA enzyme immunoassay. J Virol Methods 1994;48:81-92.
33. Simmonds P, Rose K, Graham S, Chan SW, McOmish F, Dow B, et al. Mapping of serotype-specific epitopes in the NS4 region of hepatitis C virus : use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol 1993;31:1493-503.
34. Battacherjee V, Prescott L, Pike I, Rodgers B, Bell H, El-Zayadi A, et al. Use of NS4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5, and 6. J Gen Virol 1995;76:1737-48.
35. Martinot M, Pawlotsky JM, Aumont P, Erlinger S, Dhumeaux D, Marcellin P. Serological assay to determine HCV genotype : comparison with PCR-based HCV genotyping.assay in patients with chronic hepatitis C treated with alpha interferon. In HCV : genetic heterogeneity and viral load. GEMHEP. Paris : John Libbey Eurotext 1997:101-5.
36. Van Doorn LJ, Kleter B, Pike I, Quint W. Analysis of hepatitis C virus isolates by serotyping and genotyping. J Clin Microbiol 1996; 34:1784-7.
37. Van Doorn LJ, Kleter B, Stuyver L, Maertens G, Brouwer H, Schalm S, et al. Analysis of hepatitis C virus genotypes by a line probe assay (LiPA) and correlation with antibody profiles. J Hepatol 1994;12: 122-9.
38. Dixit V, Quan S, Martin P, Larson D, Brezina M, DiNello R, et al. Evaluation of a novel serotyping system for hepatitis C virus : strong correlation with standard genotyping methodologies. J Clin Microbiol 1995;33:2978-83.
39. Dusheiko G, Schmilovitzweiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific difference in geographic origin and disease. Hepatology 1994;19:13-8.
40. McOmish F, Yap P, Dow B, Follett E, Seed C, Keller A, et al. Geographical distribution of hepatitis C virus genotypes in blood donors : an international collaborative survey. J Clin Microbiol 1994; 32:884-92.
41. Lau JYN, Mizokami M, Kolberg JA, Davis GL, Prescott L E, Ohno T, et al. Application of six HCV genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:281-9.
42. Dubois F, Desenclos JC, Mariotte N, Goudeau A, and The Collaborative Study Group. Hepatitis C in a French population-based survey, 1994 ; seroprevalence, frequency of viremia, genotype distribution, and risk factors ? Hepatology 1997;25:1490-96.
43. Gournay J, Marcellin P, Martinot-Peignoux M, Degott C, Gabriel F, Courtois F, et al. Hepatitis C virus genotypes in French blood donors. J Med Virol 1995;45:399-404.
44. Guyader D, Lefeuvre C, Jacquelinet S, Prat M, Baudouard Y, Turlin B, et al. Epidémiologie de l'infection virale C chez 1304 sujets VHC positif. Gastroenlerol Clin Biol 1998;22:375-80.
45. Lau JYN, Davis GL, Prescott LE, Maertens G, Lindsay KL, Quian KP and the Hepatits Interventional Therapy Group. Distribution of hepatitis C virus genotype determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in united states. Ann Intern Med 1996;124:868-76.
46. Lau JYN, Simmonds P, Urdea M. Implication of variations of "conserved" regions of hepatitis C virus genome. Lancet 1995;346: 425-6.
47. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie A, Vergalla J, Huofnagle J, et al. Genotypic analysis of hepatitis C virus in american patients. Hepatology 1994;20:1405-11.
48. Mellor J, Holmes E, Jarvis L, Yap P, Simmonds P. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions : implications for virus classification. J Gen Virol 1995;76:2493-507.
49. Pawlotsky JM, Tsakaris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995;171:1607-10.
50. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D, and The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease : A French survey of 6,664 patients. Hepatology 1997;26:485-90.
51. Shakil AO, Conry-Cantelina C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus : clinical, biochemical, virological, and histologic features. Ann Intern Med 1995;123:330-7.
52. Zein NN, Rakela J, Krawitt EL, Reddy R, Tominaga T, Persing DH, and the Collaborative Study Group. Hepatitis C virus genotypes in the United States : epidemiology, pathogenicity and response to Interferon therapy. Ann Intern Med. 1996;125:634-9.
53. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b infection in France and Italy. Ann Intern Med 1995;122:161-8.
54. Tokita H, Okamoto H, Lizuka H, Kishimoto J, Tsuda F, Lesmana LA, et al. Hepatitis C variants from Jakarta. Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996;77:293-301.
55. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214-23.
56. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Isopet J, Duverlie G, et al. Hepatitis C virus genotypes in France : relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepatitis 1999;6:435-43.
57. Polyak S, Faulkner G, Carithers R, Gretch D. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis : correlation with response to interferon therapy. J Infect Dis 1997;175:1101-7.
58. Hattori M, Yoshioka K, Aiyama T, Iawata K, Terazawa Y, Ishigami M, et al. Broadly reactive antibodies to hypervariable region I in HCV-infected patient sera : relation to viral loads and response to interferon. Hepatology 1998;27:1703-10.
59. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, et al. Quasispecies nature of hepatitis C virus and response to alpha interferon : significance as a predictor of direct response to interferon. J Hepatol 1997;26:6-13.
60. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative enveloppe glycoprotein variants : a potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992;89:3468-72.
61. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progresion of liver disease. Hepatology 1994;20:1144-51.
62. Spinardi L, Mazars R, Theillet D. Protocols for an improved detection of point mutations by SSCP. Nucleic Acids Res 1991;19: 4009.
63. Wilson JJ, Polyak SJ, Day TD, Gretch DR. Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis : correlation with nucleotide sequencing. J Gen Virol 1995;76:1763-71.
64. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis : a case control study. Gastroenterology 1996;111:199-205.
65. Tanaka K, Takase D, Date T. HCV infection and risk of HCC among Japanese : possible role of type 1b (II) infection. J Natl Cancer Inst 1996;88:742-6.
66. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of reccurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088-96.
67. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211-15.
68. Zeuzem S, Franka A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996:1003-9.
69. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine 1998;4:1065-7.
70. Silini E, Bono F, Cividni A, Cerino A, Bruno S, Rossi S, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21: 285-90.
71. Marcellin P, Lévy S, Erlinger S. Treatment of patients with chronic HCV infection with normal serum ALT levels. Hepatology 1995;21: 285-90.
72. Hoofnagle J, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;226:347-56.
73. Marcellin P, Boyer N, Gervais A, Martinot-Peignoux M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
74. Serfaty L. Résultats du traitement de l'hépatite C par l'interféron seul ou en association à d'autres médicaments. Gastroenterol Clin Biol 1997;21:154-66.
75. Marcellin P. Traitement de l'hépatite C par l'interféron. Gastroenterol Clin Biol 1997;21 : S81-8.
76. Marcellin P. Facteurs de réponse au traitement par l'interféron alpha chez les malades atteints d'hépatite chronique C. Perspectives thérapeutiques. Gastroenterol Clin Biol 1995;19:991-1000.
77. Pawlotsky JM, Roudot-Thoraval, Bastie A, Darthuy F, Rémiré J, Métreau JM, et al. Factors affecting treatment response to interferon alpha in chronic hepatitis C. J Infect Dis 1996;174:1-7.
78. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
79. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:112-27.
80. Poynard T, Marcellin P, Lee SS, Niederau C, Minuck GS, Ideo G, et al. Randomised trial of interferon a2b plus ribavirin for 42 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
81. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alone or in combination with ribavirin as initail treatment for chronic hepatitis C. N Engl J Med 1998;339: 1485-92.
82. Reichard O, Norkrans G, Frydén A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
83. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al. Interferon a2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
84. Zoulim F, Haem J, Ahmed SS, Chossegros P, Habersetzer F, Chevallier M, et al. Ribavirin monotherapy in patients with chronic hepatitis C. A retrospective study of 95 patients. J Viral Hepatitis 1998;5:193-8.
85. Sobesky R, Mathurin P, Charlotte F, Moussali J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis in chronic hepatitis C ; a dynamic view. Gastroenterology 1999;116:378-86.
86. Conférence internationale de consensus sur l'hépatite C. J Hepatol 1999;30:956-61.
87. Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994;3425-36.
88. Parry N, Fox G, Rowland D, Brown F, Fry E, Acharaya D, et al. Structural and serological evidence for a novel mechanism of antigenic variation in foot and mouth disease virus. Nature 1990;347:569-72.
89. Pawlotsky JM, Pellerin M, Bouvier MF, Roudot-Thoraval F, Germanidis G, Bastie A, et al. Genetic complexity of the hypervariable region I (HVRI) of hepatitis C virus : Influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998;54:256-64.
90. Yuki N, Hayashi N, Moribe T, Matsushitay, Tabata T, Inoue T, et al. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region I quasispecies. Hepatology 1997;25:439-44.
91. Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, et al. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 1997;25:697-701.
92. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus positive subjects with normal liver biochemical values. Hepatology 1995;22:418-25.
93. Evans DMA, Dunn G, Minor PD, Schild C, Cann AJ, Stanway G, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 polio vaccine genome. Nature 1985;314:548-50.
94. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995;22:30-5.
95. Naito M, Hayashi N, Moribe T, Hagiwara H, Mita E, Kanazawa Y, et al. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease. Hepatology 1995;22:407-12.
96. Asselah T, Martinot M, Levy S, Martins Amado V, Marcellin P. HVR1 quasispecies in patients with chronic hepatitis C and normal ALT (abstract). J Hepatol 1999;30:121A.
97. Remington KM, Chesebro B, Wehrly K, Pederson NC, North TW. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'deoxythymidine. J Virol 1991;65:308-12.
98. Zoulim F, Trepo C. Effets et risques des traitements antiviraux prolongés : l'exemple de l'hépatite B chronique. Gastroenterol Clin Biol 1997;21:843-7.
99. Moribe T, Hayashi N, Knazawa Y, Mitae E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995;108:789-95.
100. Okada S, Akaham Y, Suzuki H, Okamoto H, Mihio S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992;16:619-24.
101. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Bréchot C. Hepatitis C virus genome complexity correlates with response to interferon therapy : a study in French patients with chronic hepatitis C. Hepatology 1997;25:1250-4.
102. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the non structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
103. Gonzalez-Peralta RP, Quian K, She JY, Davis GL, Ohno T, Mizokami M, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996;49:242-7.
104. Gonzalez-Peralta RP, Liu WZ, Davis GL, Qian KP, Lau JYN. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy. J Viral Hepatitis 1997;4:99-106.
105. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A gene. J Clin Invest 1995;96:224-30.
106. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b : relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998:2795-805.
107. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997;113:567-72.
108. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230:217-27.
109. Gale MJ, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 1998;78:29-46.
110. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-10.
111. Kew OM, Nottay BK. Evolution of the oral polio vaccine strains in humans occurs by both mutations and intramolecular recombination. In : Chanock RM, Lerner RA, eds. Modern approaches to vaccines. Cold Spring Harbor : Cold Spring Harbor Laboratory : 357-67.
112. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40.
113. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-98.
114. Pileri P, Uematsu Y, Campagnoli S, Gali G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41.